vtx logo

request clinical advice

vtx logo sticky

scott@vtx-cpd.com

Forum Replies Created

Viewing 15 posts - 301 through 315 (of 2,024 total)
  • Author
    Posts
  • scott@vtx-cpd.com
    Keymaster

    Replying to feth eddine mazari 09/07/2024 - 12:09

    Hello!

    Great question! I will make sure Ariane sees this one and we will get back to you ASAP!

    Hope you are having a great week.

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Rosanna Vaughan 08/07/2024 - 20:33

    No problem!

    I am glad it was helpful!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Ariane N. 08/07/2024 - 20:31

    Hi Ariane,

    We’re thrilled to have you with us as a guest speaker on the 2024 Dermatology Course!

    Dermatology makes up a big percentage of small animal cases, and your expertise will undoubtedly help us work them up properly and improve the quality of life for affected pets and their parents.

    Your point about taking thorough histories and using cytology to identify secondary infections is crucial. It’s such a critical part of making a real difference in the lives of those itchy, smelly, flaky pets we see so often.

    I’m excited to kick off this course with you and am confident that everyone will gain a lot from your insights and experiences. If anyone has questions or suggestions, please don’t hesitate to post them. Let’s make this a collaborative and enriching experience for all.

    Best wishes,

    Scott

    scott@vtx-cpd.com
    Keymaster

    Replying to Janette B. 08/07/2024 - 16:08

    It is our pleasure!

    Thanks again!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Neus E. 08/07/2024 - 11:18

    Neus!

    Thank you so much for your time and consideration!

    We really appreciate your brilliance!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Felipe M. 30/06/2024 - 17:57

    Felipe!

    Thank you so much for your brilliant reply!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Emma Holt 02/07/2024 - 11:02

    Smear-1
    Smear-2
    Smear-3

    scott@vtx-cpd.com
    Keymaster

    Replying to Emma Holt 02/07/2024 - 11:02

    Hi Emma,

    Thank you so much for these really brilliant points! How is maternity leave going?

    This was a lab sample sent to an external lab, so it would not be unusual to get mild hypoglycaemia and hyperkalaemia due to transit, such as glucose consumption in transit and potassium increase due to haemolysis.

    Your key problem list and DDX are perfect! I think ruling Addison’s out in this case is a great idea. We did run a basal cortisol test which returned at 100 nmol/L. Any result over 55 nmol/L is not consistent with Addison’s, so we were confident this was not the problem in this case. I was less suspicious of Addison’s due to the lymphopenia, but it was a good rule out. I love the possible link between Addison’s and GI bleeding, anaemia, and low albumin too. We can sometimes see increases in potassium due to haemolysis, which is not uncommon in samples transported to the lab. If in doubt, I would run the sample again on a fresh one in-house.

    Regarding the possibility of liver disease, for glucose and albumin to decrease there would have to be over 75% liver function loss, which I think is less likely in this case. Albumin can decrease slightly with a negative acute phase response due to infections or inflammatory diseases. Often, globulin will increase in these situations (as it is an acute phase protein), which has not occurred in this case.

    In the emergency setting, we did a POCUS scan of the chest and abdomen, and there was no free fluid. The in-saline agglutination was negative, and we examined a blood smear. I have shared the blood smear images below. I would love to hear your thoughts.

    Again, great thinking and thank you for your valuable insights!

    Best regards,

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Hello again!

    I have some information directly from Zoetis for you too. I will try and upload the documents mentioned too:

    “Hi Scott,

    I hope you are well and nice to meet you virtually! In regards to Rosanna’s questions, a negative effect on the function of the nervous system would not be an expected adverse effect of either Librela or Solensia. As Rosanna mentions, it is not unusual for some animals with OA to also have pre-existing neurological involvement, however, as the monoclonal antibodies are large molecules, they do not distribute outside of the blood very well and cannot cross into the CNS to any significant effect (in the absence of local severe inflammation such as meningitis). It is also worth noting that Librela and Solensia are also not designed to remove all nerve growth factor (NGF) in the body, only to reduce the elevated levels found in osteoarthritic joints. To give further context to this query, in studies on the human side for anti-NGF mAbs, exhaustive evaluation was conducted for altered sympathetic function and no changes were found.

    In terms of what to advise clients in regards to potential adverse effects, the best source of information to share with them is section 4.6 within the respective SPC’s as these list the possible adverse reactions and also guide as to the frequency in which they would be expected. As these are written and amended on a regular basis from on-going pharmacovigilance (PV) and assessment from an independent regulator (the VMD), these form the most reliable guidance when discussing products with owners. Despite both products being licenced since 2021 with millions of doses being given (in excess of 14 million doses for Librela for example), few changes have been made to this section (both SPC’s attached) based on PV reports so hopefully this will give owners confidence and help guide the conversations.

    I hope this is helpful but if you have any further queries, please let me know!

    Best wishes

    Jayne

    Jayne Clark BVSc, BSc(Hons), GPCertSAM, MRCVS

    Zoetis Veterinary Consultant, East Region”

    scott@vtx-cpd.com
    Keymaster

    Replying to Yvonne McGrotty 01/07/2024 - 17:17

    Thanks pal.

    Scott x

    scott@vtx-cpd.com
    Keymaster

    Replying to Ursula Lanigan 23/06/2024 - 22:46

    Thanks for sharing!

    I totally agree with your approach! I do try and stick to one hydrolysed diet at a time and avoid mixing if possible.

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Hello everyone!

    I hope you are well!

    I wanted to share the details of a radiographic report for one of my ongoing cases, Fluffy. Based on these findings, I recommended to the owner that we proceed with a CT scan and bronchoscopy, but these were declined at the time.

    Radiographic Report:

    Findings:

    Multifocally throughout the pulmonary parenchyma, there are mild to moderate bronchocentric soft tissue opacities, some of which are slightly nodular in appearance.
    In the DV projection, within the right middle lung lobe, there is a region of increased soft tissue opacity that completely silhouettes with the pulmonary vasculature. In the left lateral projection, an air bronchogram is present.
    The cardiac silhouette is mildly displaced to the right and is otherwise normal. The pulmonary vasculature and pleural space are normal.
    The included cranial abdominal and osseous structures are normal.
    Conclusions and Recommendations:

    Multilobar moderate bronchial to structured interstitial pulmonary pattern.
    Right middle lung lobe alveolar pulmonary pattern.
    Rightward mediastinal shift.
    This constellation of findings is most consistent with inflammatory airway disease. The alveolar pattern in the right middle lung lobe combined with the rightward mediastinal shift may be indicative of lung lobe collapse due to bronchial mucus plugging.

    Fluffy-Rad

    Given the area of consolidation observed, I prescribed a two-week course of doxycycline, which seemed to resolve the clinical signs initially. However, these signs have since returned.

    This is an ongoing case, and I am currently in discussion with Fluffy’s owners about investigating further with CT and bronchoscopy to get a clearer diagnosis and guide appropriate treatment.

    Any thoughts?

    Best regards,

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Hello everyone!

    I hope you are well!

    I wanted to share the details of a radiographic report for one of my ongoing cases, Fluffy. Based on these findings, I recommended to the owner that we proceed with a CT scan and bronchoscopy, but these were declined at the time.

    Radiographic Report:

    Findings:

    Multifocally throughout the pulmonary parenchyma, there are mild to moderate bronchocentric soft tissue opacities, some of which are slightly nodular in appearance.
    In the DV projection, within the right middle lung lobe, there is a region of increased soft tissue opacity that completely silhouettes with the pulmonary vasculature. In the left lateral projection, an air bronchogram is present.
    The cardiac silhouette is mildly displaced to the right and is otherwise normal. The pulmonary vasculature and pleural space are normal.
    The included cranial abdominal and osseous structures are normal.
    Conclusions and Recommendations:

    Multilobar moderate bronchial to structured interstitial pulmonary pattern.
    Right middle lung lobe alveolar pulmonary pattern.
    Rightward mediastinal shift.
    This constellation of findings is most consistent with inflammatory airway disease. The alveolar pattern in the right middle lung lobe combined with the rightward mediastinal shift may be indicative of lung lobe collapse due to bronchial mucus plugging.

    Fluffy-Rad

    Given the area of consolidation observed, I prescribed a two-week course of doxycycline, which seemed to resolve the clinical signs initially. However, these signs have since returned.

    This is an ongoing case, and I am currently in discussion with Fluffy’s owners about investigating further with CT and bronchoscopy to get a clearer diagnosis and guide appropriate treatment.

    Any thoughts?

    Best regards,

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Ursula Lanigan 23/06/2024 - 22:40

    Hello Ursula,

    I hope you are well!

    I wanted to share the details of a radiographic report for one of my ongoing cases, Fluffy. Based on these findings, I recommended to the owner that we proceed with a CT scan and bronchoscopy, but these were declined at the time.

    Radiographic Report:

    Findings:

    Multifocally throughout the pulmonary parenchyma, there are mild to moderate bronchocentric soft tissue opacities, some of which are slightly nodular in appearance.
    In the DV projection, within the right middle lung lobe, there is a region of increased soft tissue opacity that completely silhouettes with the pulmonary vasculature. In the left lateral projection, an air bronchogram is present.
    The cardiac silhouette is mildly displaced to the right and is otherwise normal. The pulmonary vasculature and pleural space are normal.
    The included cranial abdominal and osseous structures are normal.
    Conclusions and Recommendations:

    Multilobar moderate bronchial to structured interstitial pulmonary pattern.
    Right middle lung lobe alveolar pulmonary pattern.
    Rightward mediastinal shift.
    This constellation of findings is most consistent with inflammatory airway disease. The alveolar pattern in the right middle lung lobe combined with the rightward mediastinal shift may be indicative of lung lobe collapse due to bronchial mucus plugging.

    Fluffy-Rad

    Given the area of consolidation observed, I prescribed a two-week course of doxycycline, which seemed to resolve the clinical signs initially. However, these signs have since returned.

    This is an ongoing case, and I am currently in discussion with Fluffy’s owners about investigating further with CT and bronchoscopy to get a clearer diagnosis and guide appropriate treatment.

    Any thoughts?

    Best regards,
    Scott

    scott@vtx-cpd.com
    Keymaster

    Hello again!

    I wanted to share a summary of a recent multicenter study on bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, used for alleviating pain associated with osteoarthritis (OA) in dogs. I’ve highlighted the side effects section for your reference.

    Study Overview
    Objective: Evaluate the efficacy and safety of bedinvetmab in dogs with OA.
    Design: Double-blind, randomized, multicenter, placebo-controlled study.
    Participants: 287 client-owned dogs with OA.
    Methods
    Dogs were randomized to receive either a placebo (saline, n = 146) or bedinvetmab (0.5-1.0 mg/kg, n = 141) administered monthly. After three months, dogs that responded positively to bedinvetmab continued to receive the treatment in an open-label phase.

    Results
    Efficacy:

    Treatment success was significantly higher in the bedinvetmab group compared to the placebo group from day 7 through all assessed time points.
    By day 28, 43.5% of dogs treated with bedinvetmab achieved treatment success compared to 16.9% in the placebo group (p = 0.0017).
    This success continued through days 56 (50.8%) and 84 (48.2%) in the bedinvetmab group, with less than 25% success in the placebo group.
    Sustained efficacy was demonstrated in the continuation phase.
    Safety:

    Adverse health events (AHEs) occurred at similar frequencies in both the bedinvetmab and placebo groups and were typical for a population of dogs with OA, often associated with comorbidities.
    The most frequently reported AHEs were musculoskeletal disorders, including joint pain and lameness, with joint pain being more common in the placebo group.
    During the study, two dogs in the placebo group and one dog in the bedinvetmab group died, but the deaths were not related to the study treatment.
    Common AHEs included digestive tract disorders, systemic disorders, skin disorders, and respiratory tract disorders, with some variations between the placebo and bedinvetmab groups.
    A mild transient injection site reaction was observed in one dog in each group, complicated by underlying pre-existing atopy.

    Conclusions
    The study demonstrated the effectiveness and safety of bedinvetmab administered monthly for up to nine months at 0.5-1.0 mg/kg for alleviating pain associated with canine osteoarthritis.

    Side Effects Highlight
    Musculoskeletal disorders: Joint pain and lameness were reported, with joint pain more common in the placebo group.
    Digestive tract disorders: Emesis and diarrhea were noted.
    Systemic disorders: Lethargy and anorexia were observed.
    Skin and appendages disorders: Alopecia and pruritus were reported.
    Respiratory tract disorders: Cough and tachypnea occurred.
    Renal and urinary disorders: Polyuria and urinary incontinence were observed.
    Neurological disorders: Proprioception abnormality and paresis were reported but were not common.

    Just some more evidence to share with clients!

    Best,

    Scott 🙂

Viewing 15 posts - 301 through 315 (of 2,024 total)